The Qantas board has avoided a second strike on its remuneration report as its share price hit a record so Mahnaz Angury spoke with Upstream Aviation Analyst Tim Collins to find out if its reputation is being repaired; Rhayna Bosch discusses the future of AI and the implication of GLP-1 drugs like Ozempic with ResMed CEO Michael Farrell; and SBS Finance Editor Ricardo Gonçalves looks through the day's market news with Isaac Poole from Oreana Group.